Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) have received a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $53.00.

Several research analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Robert W. Baird dropped their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Guggenheim reaffirmed a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th.

Dianthus Therapeutics Stock Down 3.2%

Shares of NASDAQ DNTH traded down $0.57 during mid-day trading on Monday, hitting $17.28. 10,459 shares of the company were exchanged, compared to its average volume of 274,496. The stock has a 50 day simple moving average of $18.97 and a 200-day simple moving average of $21.52. Dianthus Therapeutics has a 1-year low of $13.37 and a 1-year high of $32.27. The firm has a market cap of $555.85 million, a price-to-earnings ratio of -6.90 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million. Analysts anticipate that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC boosted its holdings in Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock worth $313,000 after acquiring an additional 433 shares during the period. ADAR1 Capital Management LLC boosted its holdings in Dianthus Therapeutics by 3.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company's stock worth $332,000 after acquiring an additional 602 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after acquiring an additional 618 shares during the period. Bank of New York Mellon Corp boosted its holdings in Dianthus Therapeutics by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 73,638 shares of the company's stock worth $1,336,000 after acquiring an additional 748 shares during the period. Finally, Invesco Ltd. boosted its holdings in Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after acquiring an additional 790 shares during the period. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.